Myeloproliferative Disease Program (MPD)

The MPD Program at Mount Sinai is the only comprehensive program in the Northeast for treatment of patients with myeloproliferative disease, including:

• Polycythemia Vera Essential
• Thrombocythemia
• Chronic Myeloid Leukemia Primary
• Myelofibrosis Polycythemia Vera
• Essential Thrombocythemia Chronic
• Myeloid leukemia Primary Myelofibrosis
• Polycythemia Vera Essential
• Thrombocythemia Chronic Myeloid
• Leukemia Primary Myelofibrosis
• Polycythemia Vera Essential
• Thrombocythemia Chronic Myeloid
• Leukemia Primary Myelofibrosis

This program is under the direction of internationally renowned hematologist Ronald Hoffman, MD.

Overview

The Myeloproliferative Disease (MPD) Program at Icahn School of Medicine is composed of a robust clinical trials arm and a large laboratory based arm.

The clinical component offers a number of phase I/II experimental therapies for patients with Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia. Drs. John Mascarenhas and Lewis Silverman are primarily responsible for the conduct of the clinical trials and will be joined by Dr. Shyamala Navada. Dr. Mascarenhas presented the results of an investigator initiated phase I trial of LBH589, a novel histone deacetylase inhibitor in patients with Myelofibrosis as an oral abstract at the annual American Society of Hematology meeting in 2009.

The central focus of the laboratory work of Drs. Hoffman, Anna Rita Migliaccio, Mingjiang Xu, Vesna Najfeld, Min Lu, Xiaoli Wang, Yan Li, Jiapeng Wang, Pratima Chaurasia and Camelia Iancu-Rubin centers on defining the molecular underpinnings of these neoplasms and identifying and testing novel agents in preclinical studies that will one day be used in early phase clinical trials.

Mount Sinai is the lead site and Dr. Hoffman is the Principal Investigator of a NCI-sponsored program project grant for the 38-member international Myeloproliferative Disorders Research Consortium (MPD-RC) (hyperlink to www.mpd-rc.org) that was just awarded funding for an additional 5 years. The MPD team also includes the research nurses, Amy Rodriguez and Alice Mercado; a clinical nurse practitioner, Noel George; finance manager Minu Chaudhuri; data manager Shaquanda Lippman; and administrative assistants Irma Quinones and Daniel Hathaway.